The facility called CMAX Adelaide is, according to the generics maker, ‘now Australia’s most contemporary, dedicated early‐phase clinical trial facility’. The facility is intended to provide a foundation for leading medical science organizations to deliver world‐leading research.

The facility was opened on 29 April 2016. Projects already planned to be carried out at the facility include a second study investigating an innovative wristwatch-like device which aims to provide an early warning system for hypoglycaemic events in diabetic patients and a gene therapy study developed by a Japanese biopharmaceutical company for the treatment of peripheral arterial disease.

According to South Australia’s Minister for Health Industries, the Hon Jack Snelling, ‘the South Australian Government is targeting health industry investment’. He adds that ‘an important part of this is attracting clinical trials from the United States, Europe and China’. He also said that ‘each phase I trial at CMAX will inject revenue into the local economy, sometimes as much as AU$1 million, and involve over 50 staff, including 30 nurses and 15 lab technicians’. He also pointed out that ‘Adelaide is also an important site for phase II and phase III trials, making the city a one‐stop shop for pharmaceutical companies’.

IDT Australia also recently had its transfer of ownership for 23 generics accepted by the US Food and Drug Administration (FDA). The generics include treatments for Parkinson’s disease, depression, infections, hypertension and pain [1].

Related article
ANI Pharma and IDT Australia collaborate on US generics

Reference
1. GaBI Online - Generics and Biosimilars Initiative. IDT Australia gets FDA nod for 23 generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 May 20]. Available from: www.gabionline.net/Generics/News/IDT-Australia-gets-FDA-nod-for-23-generics

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.